Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

patience. Please stay on the line and we'll be back in just a moment. Thanks for holding. We appreciate your time and patience. Please stay on the line and we'll be back in just a moment. Thank you for waiting. Your patience is appreciated. Please hold the line and we'll be right back with you. Thank you for standing by and welcome to the Crystal Biotech Q2 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentations, there will be a question-and-answer session. As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephan Peckett, Vice President of Corporate Development. Please begin. Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the second quarter of 2025. The press release is available on our website at www.crystalbio.com. We also filed our earnings 8K and 10Q with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer, Suma Krishnan, President of Research and Development, Dharana Gu, Senior Vice President and General Manager for Europe, and Kate Romano, Chief Accounting Officer. This conference call will, and our responses to questions may, contain forward-looking statements. You are cautioned not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filing. With that, I will turn the call over to Krish. Thank you. Good morning, everyone...